CGRP Forum
Send to a colleague
Register
Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

Latest news from the CGRP Forum

New information on the efficacy and tolerability of CRGP inhibitors, and comorbidity in chronic migraine.


PROMISE 2: single quarterly infusion of eptinezumab significantly reduces monthly migraine days in chronic migraine

Alder Biopharmaceuticals has announced that the pivotal phase 3 PROMISE 2 clinical trial in chronic migraine has met its primary endpoint and all key secondary endpoints for both doses of the CGRP inhibitor eptinezumab.

Read the full report here »


Study highlights safety of galcanezumab in patients with episodic migraine

Treatment-emergent adverse events are primarily mild to moderate with galcanezumab, according to results of a multicentre, double-blind, randomised phase 2b study in episodic migraine.

Read the full report here »


LIBERTY: positive results for erenumab in episodic migraine patients not responding to multiple prior preventive treatments

Novartis reports that the phase IIIb LIBERTY study has met its primary endpoint, with significantly more patients taking erenumab experiencing at least a 50% reduction from baseline in their monthly migraine days compared with patients receiving placebo.

Read the full report here »


Higher risk of physical and mental comorbidities for people with chronic migraine

Comorbidity is more frequent among people with chronic migraine compared to controls, especially among those living in areas of higher socioeconomic deprivation. These are the conclusions of an analysis of cross-sectional primary healthcare data from Scotland.

Read the full report here »

Becoming a CGRP Forum member is easy

Members have free open access simply by registering online.

We invite you to attend the 9th International CGRP Family Peptide Conference to be held from 13th - 15th February, 2018 in Santa Fe, New Mexico, USA.
We will discuss recent advances in the pharmacology, physiology and therapeutics of members of the CGRP family. The conference will cover new structural data on CGRP family receptors, development of new drugs and clinical trials, and suggestions for novel therapeutic applications of the peptides or their agonists.
The CGRP family peptides are involved in a wide range of pathophysiological conditions: migraine, obesity/diabetes, infertility, cardiovascular diseases, Alzheimer disease, inflammatory disorders, cancer and bone diseases. The basic receptor pharmacology of the agents involving family B GPCRs and the RAMP family of accessory proteins means that the area is also at the forefront of molecular pharmacology.

For more information visit: http://cgrp2018.web.unc.edu/

Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Amgen Novartis
© Copyright CGRP Forum 2018. Please click here to unsubscribe from future mailings.
‚Äč